DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma (JOURNAL OF CLINICAL ONCOLOGY, 2013)

(untitled) - Gupta, A; Love, S; Schuh, A; Collins, L; Thomason, A; Asher, R; Lisle, R; Churchman, M; Shanyinde, M; Plummer, R; Nathan, P; Danson, S; et al.